Atlas Trials

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Clinical trial NCT02124772 · COMPLETED

Trial details

NCT number
NCT02124772
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Cancer
Start date
2015-01-15
Primary completion
2020-12-29
Enrollment
139

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.